CPIC 2026 | Vaccine Innovation & Global Expansion Session – Agenda Debut
May 28,2026
How will AI and automation reshape the R&D paradigm for mRNA drugs? Where is the breakthrough point for the multibillion-dollar pneumonia vaccine market? How can the innovation incubation of multivalent combination vaccines be aligned with regulatory expectations? And how far is China‘s vaccine industry from evolving from a product exporter to a global brand?
The answers to these questions await at the Vaccine Innovation and Global Expansion Session — the full agenda of which is released today. This session brings together frontline practitioners from across the vaccine field to engage in in-depth discussions on technology transformation, product breakthroughs, innovation incubation, and global strategy.
July 22–24, Shanghai National Exhibition and Convention Center — join the pioneers of China’s vaccine industry as we explore the next horizon of innovation and global expansion.
Agenda
Engine Reimagined: The mRNA Drug R&D Revolution Driven by AI and Automation
Ying Bo: Founder, Chairman and CEO, AbogenBio
The Breakthrough Direction for Pneumococcal Vaccines
Zhu Tao: Director and CSO, CanSino Biologics Inc.
AI-Enabled Innovation Incubation of Multivalent Combination Vaccines
Hou Jian: CEO, Xinzhi Biotech
Panel Discussion: China Vaccine Innovation and Global Expansion
Liao Xiang (Moderator): Director, Clover Biopharmaceuticals, Ltd.
Zhang Jiguo: President, Vaccine Business Unit, Fosun Pharma
Wu Hongbo: General Manager, Vaccine Business Unit, China National Biotec Group
Dong Shaozhong: Vice Chairman, Walvax Biotechnology Co., Ltd.
Meng Weining: Deputy General Manager and Head of International Business, Sinovac Biotech Ltd.
Follow or Contact Us
Follow the TONACEA Official WeChat Account and scan the QR code to register. Stay updated with the latest conference news.
Public Account QR Code
Registration QR Code
Conference Service Hotline
© 2026 TONACEA (Shanghai) Technology Development Co., Ltd. All rights reserved. All rights reserved.
